?We have been exploring opportunities?
Malvviinder Singh of Ranbaxy spoke to Suprrotip Ghosh about Terapia:
How were you involved in the deal?
After taking up at the helm, I initiated the company’s inorganic expansion plan. Accordingly we took board and shareholder approval to raise equity and debt in an enabling provision. We have been exploring opportunities worldwide, and when the deal came through, we sealed it.
Why Terapia and no other company?
Terapia is the best in Romania. It is the largest independent generics company in the country. It has one of the two bioequivalence study centres in Romania. They are also the largest exporters of generics into CIS countries, including Russia, Ukraine and Poland. Besides, it has got a great team on the ground.
What are the synergies and plans for Terapia?
We need to increase capacities in R&D, and also in bio-equivalence studies. There is need to increase manufacturing facilities. We have to integrate Ranbaxy’s operations in Romania with Terapia.